Mr. Andriole is a member of Eli Lilly’s Corporate Business Development leadership team and is responsible for transactions within the Emerging Markets including in/out-licensing, JV formation and M&A.  Mr. Andriole brings to this role a proven focus on execution of complex business development projects, including his project leadership on Lilly’s $6.5bn acquisition of ImClone Systems and the $315mn acquisition of Hypnion, as well as transactions spanning multiple partnerships in China, including corporate alliances with Innovent Biologics, Hutchison Medipharma and Novast Laboratories.

Previous to this role, Mike spent 10 years in Eli Lilly's Corporate Finance and Investment Banking group, in both Indianapolis and London, leading global M&A projects for the firm and in Eli Lilly’s US operations in both finance and marketing roles.  Mr. Andriole graduated cum laude from Xavier University's Williams College of Business (BA, Finance) and earned his MBA from Indiana University's Kelley School of Business (Finance) where he is a guest lecturer on graduate business courses related to the life sciences.